Anne E. Tebo

Dr. Anne E. Tebo


Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 March 2017 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
TCTyson R. Chiaro
Tyson R. Chiaro
RSRay Soto
Ray Soto
WSW. Zac Stephens
W. Zac Stephens
JKJason L. Kubinak
Jason L. Kubinak
CPCharisse Petersen
Charisse Petersen
JRJune L. Round
June L. Round
Saccharomyces cerevisiae induces purine metabolism in mouse intestinal epithelia, resulting in an exacerbation of colitis.

1 December 2017 in Clinical and Vaccine Immunology
Verified
Journal Article
Open access
PDF file
ATAnne E. Tebo
Anne E. Tebo
The presence of antinuclear antibodies (ANAs) is a hallmark of a number of systemic autoimmune rheumatic diseases, and testing is usually performed as part of the initial diagnostic workup when suspicion of an underlying autoimmune disorder is high. The indirect immunofluorescence antibody (IFA) technique is the preferred method for detecting ANAs, as it demonstrates binding to specific intracellular structures within the cells, resulting in a number of staining patterns that are usually categorized based on the cellular components recognized and the degree of binding, as reflected by the fluorescence intensity or titer. As a screening tool, the ANA patterns can guide confirmatory testing useful in elucidating a specific clinical diagnosis or prognosis. However, routine use of ANA IFA testing as a global screening test is hampered by its labor-intensiveness, subjectivity, and limited diagnostic specificity, among other factors. This review focuses on current efforts to standardize the nomenclature of ANA patterns and on alternative methods for ANA determination, as well as on recent advances in image-based computer algorithms to automate IFA testing in clinical laboratories.

19 April 2022 in Autoimmunity Reviews
Verified
Journal Article
Closed access
BWBrandon S. Walker
Brandon S. Walker
LPLisa K. Peterson
Lisa K. Peterson
CKCurry Koening
Curry Koening
SWSandra K. White
Sandra K. White
RSRobert L. Schmidt
Robert L. Schmidt
ATAnne E. Tebo
Anne E. Tebo

1 August 2016 in The Journal of Rheumatology
Verified
Journal Article
Closed access
PDF file
SNSarada L. Nandiwada
Sarada L. Nandiwada
LPLisa K. Peterson
Lisa K. Peterson
MMMaureen D. Mayes
Maureen D. Mayes
TJTroy D. Jaskowski
Troy D. Jaskowski
EMElisabeth Malmberg
Elisabeth Malmberg
ATAnne E. Tebo
Anne E. Tebo
Objective To determine the autoantibody repertoire and clinical associations in a multiethnic cohort of American patients with systemic sclerosis (SSc). Methods There were 1000 patients with SSc (196 Hispanic, 228 African American, 555 white, and 21 other) who were screened for antinuclear antibodies (ANA), including anticentromere antibodies (ACA) by indirect immunofluorescence assay, antitopoisomerase-1 (topo-1/Scl-70) by immunodiffusion, and anti-RNA polymerase III (RNAP III) by ELISA. Sera from 160 patients with mainly nucleolar and/or speckled ANA pattern, but negative for ACA, Scl-70, and RNAP III, were further characterized by immunoprecipitation for SSc-specific antibodies. Results The prevalence of antibodies against RNAP III, Th/To, and PM/Scl did not differ significantly among the ethnic groups. The frequency of anti-Scl-70 was lowest in whites (18.0%) compared with 24.0% and 26.8% in Hispanics and African Americans (p = 0.01), respectively. Compared with African American patients, Hispanic and white subjects had a higher frequency of ACA (p < 0.0001) and lower frequency of U3-RNP (p < 0.0001). U3-RNP antibodies were uniquely higher in African American patients, independent of clinical subset, while Th/To autoantibodies were associated with limited cutaneous SSc in white subjects. Overall, Hispanic and African American patients had an earlier age of onset and a predominance of diffuse cutaneous SSc compared with their white counterparts. Conclusion SSc-specific antibodies may predict disease subset; however, the hierarchy of their prevalence differs across ethnic groups. This study provides the most extensive analysis to date on the relevance of autoantibodies in the diagnosis and clinical manifestations of SSc in Hispanic American patients.

29 May 2018 in Immunologic Research
Verified
Journal Article
Closed access
PDF file
LPLisa K. Peterson
Lisa K. Peterson
TJTroy D. Jaskowski
Troy D. Jaskowski
SLSonia L. La’ulu
Sonia L. La’ulu
ATAnne E. Tebo
Anne E. Tebo

14 April 2015 in Clinical and Experimental Immunology
Verified
Journal Article
Open access
PDF file
NHN M Heikal
N M Heikal
TJT D Jaskowski
T D Jaskowski
EME Malmberg
E Malmberg
GLG Lakos
G Lakos
DBD W Branch
D W Branch
ATAnne E. Tebo
Anne E. Tebo
Summary: Immunoglobulin (Ig)G/IgM autoantibodies to phosphatidylserine/prothrombin (aPS/PT) were evaluated individually and in combination with criteria anti-phospholipid (aPL) tests in a prospectively ascertained cohort of patients at risk for anti-phospholipid syndrome (APS). One hundred and sixty (160) consecutive requests for lupus anti-coagulant (LAC) from the University of Utah Health Sciences Center were identified during 8 weeks. Of these, 104 unique patients had additional requests for cardiolipin (aCL) and/or beta2 glycoprotein I (aβ2GPI) IgG and/or IgM; samples were retained and analysed for aPS/PT, aCL and/or aβ2GPI IgG and IgM antibodies. Following testing, a comprehensive chart review was performed and patients categorized according to their clinical diagnosis. Individual and combined sensitivities, specificities, odd ratios (OR), diagnostic accuracy for specific tests or combinations by receiver operating characteristic (ROC), area under the curve (AUC) analyses and correlations between test results were determined. The sensitivities of aPS/PT IgG/IgM (54·6/45·5%) were lower than LAC (81·8%) but higher relative to aCL IgG/IgM (27·3/0%) or aβ2GPI IgG/IgM (27·3/0%). The best correlation between LAC and any aPL test was observed with aPS/PT (P = 0·002). There was no significant difference in the diagnostic accuracies for any panel with LAC: LAC/aβ2GPI IgG/aCL IgG [AUC 0·979, OR 475·4, 95% confidence interval (CI) 23·1–9056·5, P = 0·0001 and LAC/aβ2GPI IgG/aPS/PT IgG or LAC/aPS/PT IgG/aCL IgG (AUC 0·962, OR 265·3, 14·2–4958·2, P = 0·0001). The high correlation between LAC and aPS/PT IgG/IgM in this preliminary study suggest that this marker may be useful in the evaluation of APS. More studies to determine the optimal aPL antibody tests combination are needed.